Base de dados : MEDLINE
Pesquisa : D26.049 [Categoria DeCS]
Referências encontradas : 148 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 15 ir para página                         

  1 / 148 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28448772
[Au] Autor:Tran S; Lavitas P; Stevens K; Greenwood BC; Clements K; Alper CJ; Lenz K; Price M; Hydery T; Arnold JL; Takeshita M; Bacon R; Peristere JP; Jeffrey PL
[Ad] Endereço:1 Clinical Pharmacy Services, University of Massachusetts Medical School, Shrewsbury.
[Ti] Título:The Effect of a Federal Controlled Substance Act Schedule Change on Hydrocodone Combination Products Claims in a Medicaid Population.
[So] Source:J Manag Care Spec Pharm;23(5):532-539, 2017 May.
[Is] ISSN:2376-1032
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: In 2012, hydrocodone combination products (HCPs) were the most prescribed medications in the United States. Under the Controlled Substance Act of 1970, hydrocodone alone was classified as a Schedule II drug, while HCPs were classified as Schedule III, indicating a lower risk for abuse and misuse. However, according to a Drug Enforcement Agency analysis, the addition of nonopioids has not been shown to diminish abuse potential of hydrocodone. In response to concerns for drug abuse and overdose, the Drug Enforcement Agency rescheduled HCPs to Schedule II in October 2014, with the intent of limiting overprescribing and increasing awareness of their abuse potential. However, it is unknown whether this has affected the overall claims for HCPs in a Medicaid population. OBJECTIVES: To (a) compare the trend in HCP prescription claims with select non-HCP (opioid and nonopioid) analgesic claims before and after the HCP schedule change in the Massachusetts Medicaid fee-for-service/Primary Care Clinician plan population and (b) identify if there was a change in HCP new start member and claim characteristics before and after the HCP schedule change. METHODS: This quasi-experimental, retrospective study used enrollment and pharmacy claims data to evaluate all members in the study population 1 year before and after the HCP schedule change. The number of claims for HCPs and select non-HCP analgesics was reported as the monthly rate per total population, and an interrupted time series analysis compared the change in the monthly rate of claims across groups. Members with 1 or more pharmacy claims for a new HCP prescription during a 5-month period before or after the HCP schedule change were analyzed to determine member demographics (age, gender, and number of claims) and claim characteristics (average daily dose, average quantity per claim, and days supply). RESULTS: The rate of HCP claims increased before and decreased after the HCP schedule change. Controlling for the trend during the period before the HCP schedule change, the rate of HCP claims per 1,000 members per month decreased at a greater rate than non-HCP analgesics in the period after the HCP schedule change (P < 0.001). The percentage of HCP claims for new start members decreased after the HCP schedule change (44.9% vs. 34.1% of all HCP claims pre- to post-schedule change; P < 0.001). In the group of new starts, there was not a significant difference in the average daily dose (26.3 mg vs. 26.4 mg; P = 0.69), while there was a decrease in average number of tablets dispensed per claim (from 37.1 to 20.3 tablets; P < 0.001) and an increase in the percentage of claims for a shorter days supply (from 57.7% to 81.6%; P < 0.001). CONCLUSIONS: The findings of this study suggest that the HCP schedule change may have contributed to the decrease in claims for HCPs in a Medicaid population. After the HCP schedule change, there was a trend towards decreased HCP use among new starts. DISCLOSURES: No outside funding supported this study. The authors have nothing to disclose. Study concept and design were contributed by all authors except for Arnold and Clements. Tran, Arnold, and Clements took the lead in data collection, along with Peristere, and data interpretation was performed by all the authors, except Arnold. The manuscript was written primarily by Tran, along with Lavitas, Stevens, and Greenwood, and revised by all the authors except Arnold and Peristere. A poster of this research project was presented at the Academy of Managed Care Pharmacy's 2016 Annual Meeting in San Francisco, California, April 2016.
[Mh] Termos MeSH primário: Analgésicos Opioides/administração & dosagem
Controle de Medicamentos e Entorpecentes/legislação & jurisprudência
Hidrocodona/administração & dosagem
Padrões de Prática Médica/estatística & dados numéricos
[Mh] Termos MeSH secundário: Adolescente
Adulto
Analgésicos Opioides/classificação
Substâncias Controladas/administração & dosagem
Substâncias Controladas/classificação
Combinação de Medicamentos
Feminino
Seres Humanos
Hidrocodona/classificação
Masculino
Medicaid
Meia-Idade
Estudos Retrospectivos
Estados Unidos
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Analgesics, Opioid); 0 (Controlled Substances); 0 (Drug Combinations); 6YKS4Y3WQ7 (Hydrocodone)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180111
[Lr] Data última revisão:
180111
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170428
[St] Status:MEDLINE
[do] DOI:10.18553/jmcp.2017.23.5.532


  2 / 148 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28663006
[Au] Autor:Chacko J; Greenstein J; Ardolic B; Berwald N
[Ad] Endereço:Department of Emergency Medicine, Staten Island University Hospital, Northwell Health, Staten Island, NY, United States. Electronic address: jchacko3@northwell.edu.
[Ti] Título:Effect of an emergency department opioid prescription policy on prescribing patterns.
[So] Source:Am J Emerg Med;35(9):1327-1329, 2017 Sep.
[Is] ISSN:1532-8171
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Staten Island University Hospital is located in NYC, where the opioid epidemic has resulted in significant mortalities from unintentional overdoses. In 2013 as a response to the rising threat to our community, our Emergency Department (ED) administration adopted a clinical practice policy focused on decreasing the prescription of controlled substances. The effects of this policy on our provider prescription patterns are presented here. METHODS: A retrospective chart review of patients prescribed opioids from the ED before and after policy implementation was performed. Dates chosen for analysis was November 1, 2012 through January 31, 2013 and November 1, 2013 through January 31, 2014; these time periods were used to serve as a seasonally comparative group pre and post clinical practice policy implementation. Opioids written for the treatment of cough, and for children under eighteen were excluded from analysis. Patient age, sex, diagnoses, and prescription formulation, strength, and pill number was recorded for each patient receiving an opioid prescription. RESULTS: There was a drop in the total prescriptions from 1756 to 1128 without a change in the average number of pills (12.78 vs 12.44) or average total dose prescribed (69.39 vs 68.98) mg of morphine equivalent per prescription. Additionally, there were sizable reductions in opioid prescriptions written for arthralgias/myalgias, dental pain, soft tissue injuries, and headaches. CONCLUSION: The opioid clinical policy had a clear effect in decreasing the number of patients prescribed opioids. Such policies may be the key to reducing the epidemic and saving lives from unintentional opioid overdoses.
[Mh] Termos MeSH primário: Analgésicos Opioides/uso terapêutico
Substâncias Controladas
Overdose de Drogas/epidemiologia
Prescrições de Medicamentos/estatística & dados numéricos
Serviço Hospitalar de Emergência
Padrões de Prática Médica/normas
[Mh] Termos MeSH secundário: Adulto
Controle de Medicamentos e Entorpecentes
Feminino
Seres Humanos
Masculino
Meia-Idade
New York
Política Organizacional
Estudos Retrospectivos
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Analgesics, Opioid); 0 (Controlled Substances)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170907
[Lr] Data última revisão:
170907
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170701
[St] Status:MEDLINE


  3 / 148 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28292504
[Au] Autor:Varisco TJ; Ogunsanya ME; Barner JC; Fleming ML
[Ti] Título:Pharmacists' perceptions regarding the impact of hydrocodone rescheduling on prescription volume, workflow management, and patient outcomes.
[So] Source:J Am Pharm Assoc (2003);57(2S):S51-S62, 2017 Mar - Apr.
[Is] ISSN:1544-3450
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: To determine (1) pharmacists' perceptions of how rescheduling of hydrocodone combination products (HCPs) from Drug Enforcement Agency (DEA) Schedule III to DEA Schedule II has influenced prescription volume and revenue, pharmacy workflow management, and patient outcomes; and (2) whether perceptions differed between pharmacists who support versus those who oppose HCP rescheduling. DESIGN: A cross-sectional mail survey. SETTING: Texas community pharmacies from October to December 2015. PARTICIPANTS: One thousand randomly selected, registered Texas community pharmacists drawn from the Texas State Board of Pharmacy registry. MAIN OUTCOME MEASURES: Pharmacists' perceptions, measured on a 5-point Likert scale of HCP rescheduling and its impact on prescription volume and revenue, workflow management, and patient outcomes. Measures were developed specifically for this study. RESULTS: The response rate was 17% (n = 164). The majority of pharmacists (70.4%) supported HCP rescheduling. More than 80% of respondents perceived that the volume of 2 alternative pain medications-tramadol (DEA Schedule IV) and acetaminophen with codeine (DEA Schedule III) prescriptions dispensed-either "increased" or "significantly increased" (82.0% and 85.8%, respectively) following rescheduling. Overall, pharmacists who opposed rescheduling were significantly more likely to report negative perceptions regarding revenue (P = 0.0142), inventory management (P = 0.0024), and drug shortages (P = 0.0005) than those who supported rescheduling. However, pharmacists who supported rescheduling had more positive perceptions about electronic prescribing (P <0.0115), patient safety (P <0.001), drug abuse (P <0.0001), and legitimate use (P <0.0001). CONCLUSION: Results showed that legislative efforts, such as rescheduling HCPs, influenced pharmacists' perceptions of practice and patient outcomes. Currently, little is known regarding the impact of HCP rescheduling on pharmacy practice. As new laws are passed to address the opioid epidemic in America, more research will be needed to determine whether legislation is an effective means for managing appropriate access to HCPs and other narcotic analgesics.
[Mh] Termos MeSH primário: Analgésicos Opioides/classificação
Serviços Comunitários de Farmácia/organização & administração
Hidrocodona/classificação
Farmacêuticos/organização & administração
[Mh] Termos MeSH secundário: Adulto
Analgésicos Opioides/administração & dosagem
Atitude do Pessoal de Saúde
Substâncias Controladas
Estudos Transversais
Controle de Medicamentos e Entorpecentes
Feminino
Pesquisas sobre Serviços de Saúde
Seres Humanos
Hidrocodona/administração & dosagem
Masculino
Meia-Idade
Farmacêuticos/psicologia
Texas
Fluxo de Trabalho
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Analgesics, Opioid); 0 (Controlled Substances); 6YKS4Y3WQ7 (Hydrocodone)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170904
[Lr] Data última revisão:
170904
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170316
[St] Status:MEDLINE


  4 / 148 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28286761
[Au] Autor:Lu YH; Lee LY; Chen YL; Cheng HI; Tsai WT; Kuo CC; Chen CY; Huang YB
[Ad] Endereço:Department of Pharmacy, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan; School of Pharmacy, College of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan.
[Ti] Título:Developing an App by Exploiting Web-Based Mobile Technology to Inspect Controlled Substances in Patient Care Units.
[So] Source:Biomed Res Int;2017:3195369, 2017.
[Is] ISSN:2314-6141
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:We selected iOS in this study as the App operation system, Objective-C as the programming language, and Oracle as the database to develop an App to inspect controlled substances in patient care units. Using a web-enabled smartphone, pharmacist inspection can be performed on site and the inspection result can be directly recorded into HIS through the Internet, so human error of data translation can be minimized and the work efficiency and data processing can be improved. This system not only is fast and convenient compared to the conventional paperwork, but also provides data security and accuracy. In addition, there are several features to increase inspecting quality: (1) accuracy of drug appearance, (2) foolproof mechanism to avoid input errors or miss, (3) automatic data conversion without human judgments, (4) online alarm of expiry date, and (5) instant inspection result to show not meted items. This study has successfully turned paper-based medication inspection into inspection using a web-based mobile device.
[Mh] Termos MeSH primário: Substâncias Controladas/análise
Aplicativos Móveis
Smartphone
[Mh] Termos MeSH secundário: Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Controlled Substances)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170317
[Lr] Data última revisão:
170317
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170314
[St] Status:MEDLINE
[do] DOI:10.1155/2017/3195369


  5 / 148 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27660328
[Au] Autor:Ciccone CD
[Ti] Título:Medical Marijuana: Just the Beginning of a Long, Strange Trip?
[So] Source:Phys Ther;97(2):239-248, 2017 Feb 01.
[Is] ISSN:1538-6724
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Medical marijuana continues to gain acceptance and become legalized in many states. Various species of the marijuana plant have been cultivated, and this plant can contain up to 100 active compounds known as cannabinoids. Two cannabinoids seem the most clinically relevant: Δ9-tetrahydrocannabinol (THC), which tends to produce the psychotropic effects commonly associated with marijuana, and cannabidiol (CBD), which may produce therapeutic effects without appreciable psychoactive properties. Smoking marijuana, or ingesting extracts from the whole plant orally (in baked goods, teas, and so forth), introduces variable amounts of THC, CBD, and other minor cannabinoids into the systemic circulation, where they ultimately reach the central and peripheral nervous systems. Alternatively, products containing THC, CBD, or a combination of both compounds, can be ingested as oral tablets or via sprays applied to the oral mucosal membranes. These products may provide a more predictable method for delivering a known amount of specific cannabinoids into the body. Although there is still a need for randomized controlled trials, preliminary studies have suggested that medical marijuana and related cannabinoids may be beneficial in treating people with chronic pain, inflammation, spasticity, and other conditions seen commonly in physical therapist practice. Physical therapists, therefore, should be aware of the options that are available for patients considering medical marijuana and should be ready to provide information for these patients. Clinicians also should be aware that marijuana can produce untoward effects on cognition, coordination, balance, and cardiovascular and pulmonary function and should be vigilant for any problems that may arise if patients are using cannabinoids during physical rehabilitation.
[Mh] Termos MeSH primário: Maconha Medicinal/administração & dosagem
Maconha Medicinal/efeitos adversos
[Mh] Termos MeSH secundário: Canabidiol/administração & dosagem
Canabidiol/efeitos adversos
Transtornos Cognitivos/induzido quimicamente
Confusão/induzido quimicamente
Substâncias Controladas
Depressão/induzido quimicamente
Dronabinol/administração & dosagem
Dronabinol/efeitos adversos
Vias de Administração de Medicamentos
Alucinações/induzido quimicamente
Coração/efeitos dos fármacos
Seres Humanos
Pulmão/efeitos dos fármacos
Abuso de Maconha/prevenção & controle
Transtornos da Memória/induzido quimicamente
Espasticidade Muscular/tratamento farmacológico
Náusea/induzido quimicamente
Dor/tratamento farmacológico
Fisioterapeutas
Equilíbrio Postural/efeitos dos fármacos
Papel Profissional
Vômito/induzido quimicamente
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Controlled Substances); 0 (Medical Marijuana); 19GBJ60SN5 (Cannabidiol); 7J8897W37S (Dronabinol)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170717
[Lr] Data última revisão:
170717
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:160924
[St] Status:MEDLINE
[do] DOI:10.2522/ptj.20160367


  6 / 148 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27567741
[Au] Autor:Fleming ML; Driver L; Sansgiry SS; Abughosh SM; Wanat M; Sawant RV; Ferries E; Reeve K; Todd KH
[Ad] Endereço:Department of Pharmaceutical Health Outcomes and Policy, University of Houston, College of Pharmacy, Texas Medical Center Campus, 1441 Moursund St, Houston, TX 77030, USA. Electronic address: mlflemi2@central.uh.edu.
[Ti] Título:Physicians' intention to prescribe hydrocodone combination products after rescheduling: A theory of reasoned action approach.
[So] Source:Res Social Adm Pharm;13(3):503-512, 2017 May - Jun.
[Is] ISSN:1934-8150
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The U.S. Drug Enforcement Administration (DEA) rescheduled hydrocodone combination products (HCPs) in an attempt to mitigate the prescription opioid epidemic. Many in the medical and pharmacy community expressed concerns of unintended consequences as a result of rescheduling. OBJECTIVES: This study examined physicians' intentions to prescribe HCPs after rescheduling using the framework of the theory of reasoned action (TRA). METHODS: A cover letter containing a link to the online questionnaire was sent to physicians of the Texas Medical Association who were likely to prescribe opioids. The questionnaire assessed physicians' intentions to prescribe HCPs after rescheduling. Predictor variables included attitude toward rescheduling, subjective norm toward HCP prescribing, and past prescribing behavior of schedule II prescriptions. All variables were measured on a 7-point, Likert-type scale. Intention to prescribe as a dependent variable was regressed over TRA variables and respondent characteristics. RESULTS: A total of 1176 usable responses were obtained, yielding a response rate of 13.3%. Mean (M) age was 53.07 ± 11 and most respondents were male (70%) and Caucasian (75%). Physicians held a moderately positive intention to prescribe HCPs (M = 4.36 ± 2.08), held a moderately negative attitude towards rescheduling, M = 4.68 ± 1.51 (reverse coded). Subjective norm was moderately low, M = 3.06 ± 1.78, and past prescribing behavior M = 2.43 ± 1.21. The linear regression analysis indicated that attitude (ß = 0.10; P = 0.006), subjective norm (ß = 0.35; P < 0.0001) and past prescribing behavior (ß = 0.59; P < 0.0001) were significant predictors of intention to prescribe HCPs after rescheduling. CONCLUSIONS: TRA was shown to be a predictive model of physicians' intentions to prescribe HCPs after rescheduling. Overall, physicians held a moderately positive intention to prescribe HCPs. Past behavior concerning schedule II prescribing was found to be the most significant predictor of intention. Understanding the impact of federal rule changes on pain management care and patient satisfaction is necessary to determine whether this change has produced the intended consequences without harming patients in need of HCPs.
[Mh] Termos MeSH primário: Analgésicos Opioides/administração & dosagem
Substâncias Controladas/administração & dosagem
Hidrocodona/administração & dosagem
Padrões de Prática Médica/estatística & dados numéricos
[Mh] Termos MeSH secundário: Adulto
Analgésicos Opioides/classificação
Atitude do Pessoal de Saúde
Substâncias Controladas/classificação
Estudos Transversais
Controle de Medicamentos e Entorpecentes/legislação & jurisprudência
Feminino
Seres Humanos
Hidrocodona/classificação
Intenção
Masculino
Meia-Idade
Modelos Psicológicos
Médicos/psicologia
Médicos/estatística & dados numéricos
Teoria Psicológica
Inquéritos e Questionários
Texas
Estados Unidos
United States Government Agencies
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Analgesics, Opioid); 0 (Controlled Substances); 6YKS4Y3WQ7 (Hydrocodone)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171030
[Lr] Data última revisão:
171030
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160829
[St] Status:MEDLINE


  7 / 148 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26858007
[Au] Autor:Elkins KM; Weghorst AC; Quinn AA; Acharya S
[Ad] Endereço:Chemistry Department, Towson University, 8000 York Road, Towson, MD, 21252, USA.
[Ti] Título:Colour quantitation for chemical spot tests for a controlled substances presumptive test database.
[So] Source:Drug Test Anal;9(2):306-310, 2017 Feb.
[Is] ISSN:1942-7611
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Crime scene investigators (CSIs) often encounter unknown powders, capsules, tablets, and liquids at crime scenes, many of which are controlled substances. Because most drugs are white powders, however, visual determination of the chemical identity is difficult. Colourimetric tests are a well-established method of presumptive drug identification. Positive tests are often reported differently, however, because two analysts may perceive colour or record colourimetric results in different ways. In addition to perceiving colour differently, it is very common for there to be poor visibility conditions (e.g. rain, darkness) while performing these tests, further obscuring the results. In order to address these concerns and to create uniformity in the reporting of on-site colourimetric test results, this study has evaluated two of the state-of-the-art apps (ColorAssist® and Colorimeter®) for reporting the colour test results quantitatively in red-green-blue (RGB) format. The compiled library database of presumptive test results contains over 3300 data points including over 800 unique drug/test combinations. Variations observed between test replicates, from performing a test on different days, recording with a different device type (e.g. iPod Touch, iPhone models 4, 5c, 5s, or 6), and using different quantities of drug are discussed. Overall, the least variation in Euclidian norm was observed using ColorAssist® with the camera light (25.1±22.1) while the variation between replicates and data recorded using different devices was similar. The resulting library is uploaded to a smartphone application aimed to aid in identifying and interpreting suspected controlled substance evidence. Copyright © 2016 John Wiley & Sons, Ltd.
[Mh] Termos MeSH primário: Colorimetria/métodos
Substâncias Controladas/análise
[Mh] Termos MeSH secundário: Cor
Bases de Dados de Produtos Farmacêuticos
Seres Humanos
Aplicativos Móveis
Detecção do Abuso de Substâncias/métodos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Controlled Substances)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170630
[Lr] Data última revisão:
170630
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160210
[St] Status:MEDLINE
[do] DOI:10.1002/dta.1949


  8 / 148 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26643483
[Au] Autor:King C; McCue A
[Ad] Endereço:Longmont United Hospital, USA.
[Ti] Título:Drugs down the drain: When nurses object.
[So] Source:Nurs Ethics;24(4):452-461, 2017 Jun.
[Is] ISSN:1477-0989
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The authors examine the nursing practice of disposing unaltered controlled substances into public water systems as an issue for nurses concerned with the environmental harm it can cause. A summary of the history of controlled substance management reveals inconsistencies in the interpretation of current regulations that have led to disposal policies that vary by institution, according to a benchmarking survey of regional hospitals. Much attention has been given to the phenomenon of conscientious objection in the context of patient care that conflicts with a nurse's moral integrity. Nurses who are compelled to dispose narcotics down drains may also face this struggle. The authors submit that this disposal method is based on a type of double effect logic where preventing diversion is viewed as a good effect of flushing unused controlled substances that outweighs any harm it may cause, though there is little evidence to support this conclusion. Consequently, the topic deserves further study so that nurse managers and administrators can support and offer alternatives to nurses who object to flushing drugs down the drain.
[Mh] Termos MeSH primário: Atitude do Pessoal de Saúde
Substâncias Controladas/provisão & distribuição
Eliminação de Resíduos de Serviços de Saúde/normas
Enfermeiras e Enfermeiros/psicologia
Poluição da Água/ética
[Mh] Termos MeSH secundário: Seres Humanos
Eliminação de Resíduos de Serviços de Saúde/métodos
Inquéritos e Questionários
Estados Unidos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Controlled Substances); 0 (Medical Waste Disposal)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170815
[Lr] Data última revisão:
170815
[Sb] Subgrupo de revista:N
[Da] Data de entrada para processamento:151209
[St] Status:MEDLINE
[do] DOI:10.1177/0969733015614882


  9 / 148 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28068052
[Au] Autor:Drug Enforcement Administration, Department of Justice
[Ti] Título:Revision of Import and Export Requirements for Controlled Substances, Listed Chemicals, and Tableting and Encapsulating Machines, Including Changes To Implement the International Trade Data System (ITDS); Revision of Reporting Requirements for Domestic Transactions in Listed Chemicals and Tableting and Encapsulating Machines; and Technical Amendments. Final rule.
[So] Source:Fed Regist;81(251):96992-7044, 2016 12 30.
[Is] ISSN:0097-6326
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The Drug Enforcement Administration is updating its regulations for the import and export of tableting and encapsulating machines, controlled substances, and listed chemicals, and its regulations relating to reports required for domestic transactions in listed chemicals, gamma-hydroxybutyric acid, and tableting and encapsulating machines. In accordance with Executive Order 13563, the Drug Enforcement Administration has reviewed its import and export regulations and reporting requirements for domestic transactions in listed chemicals (and gamma-hydroxybutyric acid) and tableting and encapsulating machines, and evaluated them for clarity, consistency, continued accuracy, and effectiveness. The amendments clarify certain policies and reflect current procedures and technological advancements. The amendments also allow for the implementation, as applicable to tableting and encapsulating machines, controlled substances, and listed chemicals, of the President's Executive Order 13659 on streamlining the export/import process and requiring the government-wide utilization of the International Trade Data System (ITDS). This rule additionally contains amendments that implement recent changes to the Controlled Substances Import and Export Act (CSIEA) for reexportation of controlled substances among members of the European Economic Area made by the Improving Regulatory Transparency for New Medical Therapies Act. The rule also includes additional substantive and technical and stylistic amendments.
[Mh] Termos MeSH primário: Comércio/legislação & jurisprudência
Substâncias Controladas
Controle de Medicamentos e Entorpecentes/legislação & jurisprudência
Desvio de Medicamentos sob Prescrição/legislação & jurisprudência
[Mh] Termos MeSH secundário: Processamento Automatizado de Dados/legislação & jurisprudência
Cápsulas
Composição de Medicamentos/instrumentação
Rotulagem de Medicamentos/legislação & jurisprudência
Embalagem de Medicamentos/legislação & jurisprudência
Efedrina
Seres Humanos
Hidroxibutiratos
Sistemas de Informação/legislação & jurisprudência
Fenilpropanolamina
Projetos Piloto
Desvio de Medicamentos sob Prescrição/prevenção & controle
Pseudoefedrina
Comprimidos
Estados Unidos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Capsules); 0 (Controlled Substances); 0 (Hydroxybutyrates); 0 (Tablets); 33RU150WUN (Phenylpropanolamine); 7CUC9DDI9F (Pseudoephedrine); GN83C131XS (Ephedrine)
[Em] Mês de entrada:1701
[Cu] Atualização por classe:170118
[Lr] Data última revisão:
170118
[Sb] Subgrupo de revista:T
[Da] Data de entrada para processamento:170110
[St] Status:MEDLINE


  10 / 148 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28059432
[Au] Autor:Shields LB; Nasraty S; Bell AD; Vinayakan AN; Gudibanda RS; Hester ST; Honaker JT
[Ad] Endereço:Norton Neuroscience Institute, Norton Healthcare, Louisville, Kentucky.
[Ti] Título:Primary care providers' prescribing practices of opioid controlled substances.
[So] Source:J Opioid Manag;12(6):397-403, 2016 Nov/Dec.
[Is] ISSN:1551-7489
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: Prescription opioid abuse poses a significant public health concern. House Bill 1 (HB1) was enacted in 2012 to address prescription drug abuse in Kentucky. The authors investigated the impact of HB1 on primary care providers' (PCPs) prescribing practices of Schedule II controlled substances. DESIGN: Retrospective evaluation of PCPs' prescribing practices in an adult outpatient setting. METHODS: A review of the prescribing practices for Schedule II controlled substances written by 149 PCPs. The number of prescriptions for Schedule II controlled substances written by 149 PCPs was compared to the top 10 PCP prescribers. Attention was focused on providers who wrote for oxycontin and/or opana and prescriptions with > 90 pills dispensed. RESULTS: The top 10 PCP prescribers accounted for 38.4 percent of the Schedule II controlled substances and 47.8 percent of the Schedule II controlled substances with > 90 pills dispensed. Of the 60 PCPs who prescribed opana and/or oxycontin, the average number of prescriptions was 14.7 compared to 51.0 for the top 10 PCP prescribers. The average percentage of Schedule II controlled substance prescriptions compared to the total number of prescriptions was 27.9 percent for the top 10 PCP prescribers and 7.05 percent of all PCPs. The average percentage of office visits with Schedule II controlled substance prescriptions compared to total office visits was 24.8 percent for the top 10 PCP prescribers versus 7.7 percent for all PCPs. CONCLUSIONS: Further scrutiny is warranted to more closely analyze provider opioid prescribing habits and ensure that the providers at our Institution are prescribing Schedule II controlled substances in compliance with HB1.
[Mh] Termos MeSH primário: Analgésicos Opioides/uso terapêutico
Substâncias Controladas/efeitos adversos
Prescrições de Medicamentos/estatística & dados numéricos
Padrões de Prática Médica/estatística & dados numéricos
Atenção Primária à Saúde/estatística & dados numéricos
[Mh] Termos MeSH secundário: Adulto
Seres Humanos
Oxicodona/uso terapêutico
Uso Indevido de Medicamentos sob Prescrição
Estudos Retrospectivos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Analgesics, Opioid); 0 (Controlled Substances); CD35PMG570 (Oxycodone)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171004
[Lr] Data última revisão:
171004
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170107
[St] Status:MEDLINE



página 1 de 15 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde